Courtagen Life Sciences Integrates SimulConsult's Genome-Phenome Analyzer to Enhance the Clinical Genetic Analysis for Neurological and Metabolic Disorders

Courtagen signed a licensing agreement with SimulConsult to incorporate their innovative diagnostic software into Courtagen's ZiPhyr® *Molecular Information Platform.*

WOBURN, MA, April 9, 2014 – Courtagen Life Sciences, an innovative molecular information company, announced today an agreement with SimulConsult, Inc. to incorporate SimulConsult's Genome-Phenome Analyzer into their process for clinical interpretations of genetic tests.

Inherited mitochondrial diseases, seizure disorders, and intellectual disability are all areas where achieving a definitive diagnosis is challenging. What differentiates Courtagen is the power of their internal genomics database and expert interpretation resulting from genotype and phenotype correlation. Courtagen combines their state-of-the-art Next Generation Sequencing capabilities, the extensive experience of their clinical and scientific teams, and the reliable, accurate, and reproducible process of interpretation enhanced by the SimulConsult diagnostic decision support system. Importantly, it does so in a way that is efficient – helping to keep costs down and improving turnaround times.

"By enabling the submission of clinical data via the SimulConsult Patient Summary, Courtagen can now incorporate the full richness of patient information into the genomic analysis and interpretation," said Michael Segal MD, PhD, Founder and Chief Scientist of SimulConsult.

"Collecting detailed information on the clinical presentation (phenotype) and correlating it with DNA sequence data (genotype) drives high confidence and added value in the personalized interpretation of the patient's report," said Christine Stanley, PhD, FACMG, Chief Director of Clinical Genomics of Courtagen. "Integrating SimulConsult's Genotype-Phenotype Analyzer is a powerful addition to our clinical interpretation."

"We look forward to fully integrating SimulConsult into our ZiPhyr® molecular information platform," said Brendan McKernan, President of Courtagen. "The combination of these two platforms will enhance the quality of the clinical information in our database, provide greater personalization of patient reports, and enable actionable results for medical providers and pharmaceutical companies looking to optimize treatments and therapy options."

About Courtagen Life Sciences, Inc.
Courtagen is a privately-held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and autism spectrum disorders. Courtagen's state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype,

and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive diagnosis for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.

About SimulConsult, Inc.
SimulConsult, Inc. is a privately-held medical software company. Its diagnostic decision support system provides a simultaneous consult on the patient's diagnosis that enables faster, more accurate, and lower cost clinical diagnosis and genome interpretation. Built on its core platform are tools for clinicians, labs, and insurers. SimulConsult's prize winning Genome-Phenome Analyzer enables a geneticists to combine annotated genome variant tables with detailed phenotypic data provided by the referring clinician, including key information about pertinent negatives and onset of individual findings. The full power of genomic data plus phenomic data is utilized to arrive at a diagnosis in seconds. An innovative measure of pertinence of genes focuses attention on the genes accounting for the clinical picture, in a hypothesis-independent way with no restrictions about the type of inheritance or the numbers of genes involved. After receiving the genome-phenome results, the referring clinician can use the results interactively, by adding information from confirmatory tests or adding new findings that develop over time. For additional information, please visit www.simulconsult.com.

Contact:
Lori Emrick
Sr. Director Marketing
lori.emrick@courtagen.com
877-395-7608
###